


PHARMACEUTICAL 2022



Cyclerion Therapeutics Inc. Rank 404 of 475





PHARMACEUTICAL 2022



Cyclerion Therapeutics Inc. Rank 404 of 475

The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is -445%, being 168% points below the market average of -276%.

| Input Variable | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current | 55,457 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 11,085 |
| Liabilities, Non-Current | 0 |
| Other Assets | 3,809 |
| Other Compr. Net Income | 0 |
| Other Expenses | 881 |
| Other Liabilities | 0 |
| Other Net Income | 3,548 |
| Property and Equipment | 65 |
| Research and Development | 37,636 |
| Revenues | 3,942 |
| Selling, General and Administrative Expense | 20,620 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 59,331 |
| Liabilities | 11,085 |
| Expenses | 59,137 |
| Stockholders Equity | 48,246 |
| Net Income | -51,647 |
| Comprehensive Net Income | -51,647 |
| Economic Capital Ratio | -445% |